Hemodialysis and Peritoneal Dialysis Market Segments and Growth by 2028

The hemodialysis and peritoneal dialysis market is projected to reach US$ 130,370.18 million by 2028 from US$ 89,851.61 million in 2022; it is expected to grow at a CAGR of 6.4% from 2022 to 2028.

There are two kinds of dialysis. In hemodialysis, blood is pumped out of patient's body to an artificial kidney machine and returned to the patient's body by tubes connected to the machines. In peritoneal dialysis, the inside lining of patient's own belly acts as a natural filter.

The hemodialysis and peritoneal dialysis market is segmented on the basis of type, product, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The hemodialysis and peritoneal dialysis market report offers insights and in-depth analysis of the market, emphasizing parameters such as market size, trends, technological advancements, and market dynamics, as well as the analysis of the competitive landscape of the globally leading market players. Furthermore, the report includes the impact of the COVID-19 pandemic on the hemodialysis and peritoneal dialysis market across all the regions.

The growth of the hemodialysis and peritoneal dialysis market is attributed to the increase in the number of ESRD patients, rise in incidence of kidney failure and chronic renal dysfunction among population, and dearth of organ donors. However, the reimbursement concerns in emerging markets restrict the market growth.

Hemodialysis and Peritoneal Dialysis Market: Strategic Insights

Market Insights                               

Increasing Prevalence of Kidney Diseases Drives Hemodialysis and Peritoneal Dialysis Market Growth

Chronic kidney disease (CKD) and acute kidney injury (AKI) are conditions in which the kidneys are damaged and cannot filter blood properly. Because of this, excess fluid and waste from blood remain in the body, which may cause other health problems such as heart disease and stroke. CKD usually worsens over time, even though treatment has shown slow progression. If CKD is left untreated, it can progress to kidney failure and early cardiovascular disease. In CKD, when the kidneys stop working, dialysis or kidney transplant is needed for survival. When treated with dialysis or kidney transplant, this kidney failure is called end-stage renal disease (ESRD). According to the Centers for Disease Control and Prevention (CDC), approximately 36 million adults are suffering from CKD in the US. Further, every 24 hours, 360 people begin dialysis treatment for kidney failure. In 2017, 697.5 million cases of CKD (all stages) were recorded worldwide, for a global prevalence of 9.1%. The increasing prevalence of ESRD is also one of the major factors driving the market. For instance, according to the United States Renal Data System (USRDS), nearly 786,000 people in the country are living with end-stage kidney disease (ESKD), also known as an end-stage renal disease (ESRD). Thus, the increasing prevalence of chronic kidney disease, acute kidney injury, and end-stage renal disease, which leads to the condition of dialysis, is driving the hemodialysis and peritoneal dialysis market.

Type-Based Insights

Based on type, the hemodialysis and peritoneal dialysis market is bifurcated into hemodialysis and peritoneal dialysis. In 2022, the hemodialysis segment held a larger share of the market. Moreover, the same segment is expected to register a higher CAGR of 6.7% during the forecast period.

Product-Based Insights

Based on product, the hemodialysis and peritoneal dialysis market is segmented into devices, consumables, and services. The services segment held the largest market share in 2022. However, the consumables segment is anticipated to register the highest CAGR of 7.5% during the forecast period.

End User-Based Insights

Based on end user, the hemodialysis and peritoneal dialysis market is segmented into hospital-based and home-based. The hospital-based segment held a larger share in 2022. However, the home-based segment is expected to register a higher CAGR of 7.4% during the forecast period.

The hemodialysis and peritoneal dialysis market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio worldwide, as well as to meet the growing demands.

The regional trends and factors influencing the Hemodialysis and Peritoneal Dialysis Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Hemodialysis and Peritoneal Dialysis Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Hemodialysis and Peritoneal Dialysis Market Report Scope

Hemodialysis and Peritoneal Dialysis Market Players Density: Understanding Its Impact on Business Dynamics

The Hemodialysis and Peritoneal Dialysis Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

By Geography

Based on geography, the hemodialysis and peritoneal dialysis market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). A few of the leading players involved in the market are Fresenius Medical Care AG & Co KGaA; DaVita Inc.; Baxter International Inc.; B. Braun Melsungen AG; Diaverum; Nipro Medical Corporation; Asahi Kasei Medical Co., Ltd.; Rockwell Medical, Inc.; and Dialife SA.